Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial

CONTEXT: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. OBJECTIVES: We assessed the cardiovascular safety profile of abaloparatide. DESIGN: Review of heart rate (HR...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Endocrinol Metab
Main Authors: Cosman, Felicia, Peterson, Linda R, Towler, Dwight A, Mitlak, Bruce, Wang, Yamei, Cummings, Steven R
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Clinical Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7500469/
https://ncbi.nlm.nih.gov/pubmed/32658264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa450
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items